All In Biotech

Drug Trial Radar · NCT06942936

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

An Open-label, Fixed-sequence and Two-part Study to Assess the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on the Pharmacokinetics of Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

May 28, 2025

Primary completion

Jan 28, 2026

Study completion Jan 28, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the impact of multiple doses of itraconazole on the pharmacokinetics (PK) of AZD5004 in healthy participants (Part A), and to assess the impact of multiple doses of AZD5004 on the PK of Combined Oral Contraceptives (COCs) in healthy female participants (Part B).

Conditions

  • Healthy Participants

Interventions

  • AZD5004Drug

    AZD50004 is administered orally as a tablet.

  • ItraconazoleDrug

    Itraconazole is administered orally as a capsule.

  • EE/LNGDrug

    EE/LNG is administered orally in the form of tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Area under concentration-time curve from time zero to infinity (AUCinf) of AZD5004Time frame: Day 1 and Day 10
  2. Part A: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of AZD5004Time frame: Day 1 and Day 10
  3. Part A: Maximum observed drug concentration (Cmax) of AZD5004Time frame: Day 1 and Day 10
  4. Part A: Terminal elimination half-life (t1/2λz) of AZD5004Time frame: Day 1 and Day 10
  5. Part A: Time to reach maximum observed concentration (tmax) of AZD5004Time frame: Day 1 and Day 10
  6. Part A: Apparent total body clearance (CL/F) of AZD5004Time frame: Day 1 and Day 10
  7. Part A: Apparent volume of distribution based on the terminal phase (Vz) of AZD5004Time frame: Day 1 and Day 10
  8. Part B: Area under concentration-time curve from time zero to infinity (AUCinf) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
  9. Part B: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
  10. Part B: Maximum observed drug concentration (Cmax) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
  11. Part B: Terminal elimination half-life (t1/2λz) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
  12. Part B: Time to reach maximum observed concentration (tmax) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
  13. Part B: Apparent total body clearance (CL/F) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78
  14. Part B: Apparent volume of distribution based on the terminal phase (Vz) of EE/LNGTime frame: Day 1, Day 8, Day 50 and Day 78

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Baltimore, Maryland

  • Research Site

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.